Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
   
Ask the Experts About

Understanding Your LabsUnderstanding Your Labs
           
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


Isentress Once A Day Dosing In Europe?
Jan 13, 2010

You recently responded to a question by stating about Isentress/Truvada that: "The data looked very good for taking both of these together once daily in clinical trials and this once daily combination has been approved recently in Europe."

Are you sure about this? I know Isentress has been approved in Europe for treatment-naive, as it is here in the US, but I was under the impression that the dosing is 400 mg. twice a day (BID).

I have heard that the clinical trials looking at once daily dosing for Isentress are going very well, but they aren't officially over until sometime in 2011.

Please clear up this confusion if you can.

Thank you very much for all your great work.

Response from Dr. Holodniy

My bad. Not approved yet.



Previous
Baraclude 0.5mg resistance
Next
Precum/co-infection in sero-discordant couples

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement